Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas

Stephan D. Thomé, Charles L. Loprinzi, Michael P. Heldebrant

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Objective: To facilitate both better physician understanding of prognostic information (baseline and with adjuvant interferon) for individual patients who present with resectable melanomas and more informed patient decisions about whether they should receive adjuvant high-dose interferon therapy after resection of primary melanomas. Patients and Methods: Baseline survival estimates were derived from a surgical database composed of 17,600 patients with complete clinical, pathologic, and follow-up data. Potential survival benefits ascribed to adjuvant interferon were obtained from results of a meta-analysis of Eastern Cooperative Oncology Group studies, which provided evidence for a uniform relative benefit of high-dose interferon across different baseline risk groups. A mathematical formula was then applied to these data to allow for individual prognostic information. Results: The 5-year survival benefits in patients who received high-dose interferon after surgery, using the assumptions of the provided prognoses and interferon survival improvements, ranged up to 13%. Conclusions: These data should allow for a better understanding of baseline prognosis in individual patients and a better understanding of the potential benefits of adjuvant interferon. They should also help patients make more informed decisions regarding their treatment options.

Original languageEnglish (US)
Pages (from-to)913-917
Number of pages5
JournalMayo Clinic proceedings
Issue number9
StatePublished - Sep 2002

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas'. Together they form a unique fingerprint.

Cite this